{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:49:39Z","timestamp":1791521379745,"version":"4.3.4"},"reference-count":53,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2026,8,20]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/bmjmed-2026-002780","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:10:12Z","timestamp":1791519012000},"page":"e002780","source":"Crossref","is-referenced-by-count":0,"title":["Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3709-9326","authenticated-orcid":false,"given":"Daniela C","family":"Gonz\u00e1lez-Cruz","sequence":"first","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"},{"name":"Endocrinology Division, Department of Internal Medicine, Dr Jose Eleuterio Gonzalez University Hospital, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-6432","authenticated-orcid":false,"given":"Mariano","family":"Garcia-Campa","sequence":"additional","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3661-4912","authenticated-orcid":false,"given":"Pablo Jos\u00e9","family":"Moreno-Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-0547","authenticated-orcid":false,"given":"Andres","family":"Avalos-Bishop","sequence":"additional","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"},{"name":"Endocrinology Division, Department of Internal Medicine, Dr Jose Eleuterio Gonzalez University Hospital, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3958-1267","authenticated-orcid":false,"given":"Dulce Mar\u00eda","family":"Manzanares-Gallegos","sequence":"additional","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"},{"name":"Endocrinology Division, Department of Internal Medicine, Dr Jose Eleuterio Gonzalez University Hospital, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4629-2579","authenticated-orcid":false,"given":"Fernanda M","family":"Garcia-Garcia","sequence":"additional","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8221-6578","authenticated-orcid":false,"given":"Jan Alejandro","family":"Montiel Labastida","sequence":"additional","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6609-9483","authenticated-orcid":false,"given":"Jos\u00e9 Gerardo","family":"Gonz\u00e1lez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"},{"name":"Endocrinology Division, Department of Internal Medicine, Dr Jose Eleuterio Gonzalez University Hospital, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0931-7851","authenticated-orcid":false,"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, AB, Canada"},{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-8089","authenticated-orcid":false,"given":"Veena","family":"Manja","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of California Davis, Sacramento, CA, USA"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Olav Vandvik","sequence":"additional","affiliation":[{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"},{"name":"Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6182-9969","authenticated-orcid":false,"given":"Thomas","family":"Agoritsas","sequence":"additional","affiliation":[{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Lawrence, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3022-5302","authenticated-orcid":false,"given":"Ren\u00e9","family":"Rodr\u00edguez-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Aut\u00f3noma de Nuevo Le\u00f3n Facultad de Medicina, Monterrey, Mexico"},{"name":"Endocrinology Division, Department of Internal Medicine, Dr Jose Eleuterio Gonzalez University Hospital, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100821100629000_5.1.e002780.1","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2026100821100629000_5.1.e002780.2","doi-asserted-by":"publisher","DOI":"10.2337\/DCI22-0034"},{"key":"2026100821100629000_5.1.e002780.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1091","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"2026100821100629000_5.1.e002780.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l5887","article-title":"Benefits and harms of intensive glycemic control in patients with type 2 diabetes","volume":"367","author":"Rodriguez-Gutierrez","year":"2019","journal-title":"BMJ"},{"key":"2026100821100629000_5.1.e002780.5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S2213-8587(15)00468-4","article-title":"Shared decision making in endocrinology: present and future directions","volume":"4","author":"Rodriguez-Gutierrez","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100821100629000_5.1.e002780.6","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2021.658817","article-title":"Making Diabetes Care Fit-Are We Making Progress?","volume":"2","author":"Ruissen","year":"2021","journal-title":"Front Clin Diabetes Healthc"},{"key":"2026100821100629000_5.1.e002780.7","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-021-01433-0","article-title":"Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes","volume":"21","author":"Rodr\u00edguez-Guti\u00e9rrez","year":"2021","journal-title":"Curr Diab Rep"},{"key":"2026100821100629000_5.1.e002780.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022622"},{"key":"2026100821100629000_5.1.e002780.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.09.003"},{"key":"2026100821100629000_5.1.e002780.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049130","article-title":"Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review","volume":"11","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2021","journal-title":"BMJ Open"},{"key":"2026100821100629000_5.1.e002780.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082071","article-title":"Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline","volume":"390","author":"Agarwal","year":"2025","journal-title":"BMJ"},{"key":"2026100821100629000_5.1.e002780.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026100821100629000_5.1.e002780.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"key":"2026100821100629000_5.1.e002780.14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2017.05.018","article-title":"Incorporating patients\u2019 views in guideline development: a systematic review of guidance documents","volume":"88","author":"Selva","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2026100821100629000_5.1.e002780.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.03.013"},{"key":"2026100821100629000_5.1.e002780.16","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0089-7"},{"key":"2026100821100629000_5.1.e002780.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.01.013"},{"key":"2026100821100629000_5.1.e002780.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.05.011"},{"key":"2026100821100629000_5.1.e002780.19","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2017-110668"},{"key":"2026100821100629000_5.1.e002780.20","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S14477"},{"key":"2026100821100629000_5.1.e002780.21","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.529377"},{"key":"2026100821100629000_5.1.e002780.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2012.703633","article-title":"Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results","volume":"15 Suppl 2","author":"Jendle","year":"2012","journal-title":"J Med Econ"},{"key":"2026100821100629000_5.1.e002780.23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13300-012-0015-6","article-title":"A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice","volume":"4","author":"Evans","year":"2013","journal-title":"Diabetes Ther"},{"key":"2026100821100629000_5.1.e002780.24","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2147\/PPA.S90842","article-title":"Evaluating preferences for profiles of GLP-1 receptor agonists among injection-na\u00efve type 2 diabetes patients in the UK","volume":"9","author":"Gelhorn","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"2026100821100629000_5.1.e002780.25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1185\/03007995.2015.1117433","article-title":"A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes","volume":"32","author":"Hauber","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2026100821100629000_5.1.e002780.26","doi-asserted-by":"publisher","DOI":"10.1177\/2042018815595584"},{"key":"2026100821100629000_5.1.e002780.27","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2147\/PPA.S109289","article-title":"Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan","volume":"10","author":"Gelhorn","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2026100821100629000_5.1.e002780.28","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-017-2648-7","article-title":"Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes","volume":"17","author":"Matza","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2026100821100629000_5.1.e002780.29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13300-017-0237-8","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom","volume":"8","author":"Qin","year":"2017","journal-title":"Diabetes Ther"},{"key":"2026100821100629000_5.1.e002780.30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13300-017-0230-2","article-title":"Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Na\u00efve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study","volume":"8","author":"Qin","year":"2017","journal-title":"Diabetes Ther"},{"key":"2026100821100629000_5.1.e002780.31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2147\/PPA.S159620","article-title":"Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes","volume":"12","author":"Matza","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2026100821100629000_5.1.e002780.32","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2018.1465903","article-title":"Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes","volume":"34","author":"Matza","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2026100821100629000_5.1.e002780.33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.19080\/CRDOJ.2018.06.555700","article-title":"Preferences for Attributes of Medications among Patients with Type 2 Diabetes: A Cross-Medication Class Comparison of Injection Therapies","volume":"6","author":"Poon","year":"2018","journal-title":"CRDOJ"},{"key":"2026100821100629000_5.1.e002780.34","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/13696998.2019.1609482","article-title":"Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy","volume":"22","author":"Boye","year":"2019","journal-title":"J Med Econ"},{"key":"2026100821100629000_5.1.e002780.35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13300-019-0591-9","article-title":"Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment","volume":"10","author":"Brooks","year":"2019","journal-title":"Diabetes Ther"},{"key":"2026100821100629000_5.1.e002780.36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/dom.13902","article-title":"Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)","volume":"22","author":"Matza","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026100821100629000_5.1.e002780.37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12325-020-01561-1","article-title":"Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment","volume":"38","author":"Igarashi","year":"2021","journal-title":"Adv Ther"},{"key":"2026100821100629000_5.1.e002780.38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jval.2020.01.023","article-title":"Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment","volume":"23","author":"Ozdemir","year":"2020","journal-title":"Value Health"},{"key":"2026100821100629000_5.1.e002780.39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/dom.14244","article-title":"Patients\u2019 preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study","volume":"23","author":"Boye","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026100821100629000_5.1.e002780.40","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s13300-021-01097-9","article-title":"Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments","volume":"12","author":"Boye","year":"2021","journal-title":"Diabetes Ther"},{"key":"2026100821100629000_5.1.e002780.41","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s11136-021-02808-2","article-title":"Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes","volume":"30","author":"Matza","year":"2021","journal-title":"Qual Life Res"},{"key":"2026100821100629000_5.1.e002780.42","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.2147\/PPA.S391719","article-title":"Patients\u2019 Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists","volume":"16","author":"Banjara","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"2026100821100629000_5.1.e002780.43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2147\/PPA.S355638","article-title":"Patients\u2019 Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation","volume":"16","author":"Costa Gil","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"2026100821100629000_5.1.e002780.44","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1007\/s12325-022-02181-7","article-title":"Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment","volume":"39","author":"Shubrook","year":"2022","journal-title":"Adv Ther"},{"key":"2026100821100629000_5.1.e002780.45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2147\/PPA.S401465","article-title":"The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes","volume":"17","author":"Gelhorn","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"2026100821100629000_5.1.e002780.46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2023.29.2.139","article-title":"Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment","volume":"29","author":"Panchal","year":"2023","journal-title":"JMCP"},{"key":"2026100821100629000_5.1.e002780.47","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijcard.2022.09.009","article-title":"Patient preferences for newer oral therapies in type 2 diabetes","volume":"371","author":"Savarese","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026100821100629000_5.1.e002780.48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41591-022-02121-6","article-title":"Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study","volume":"29","author":"Shields","year":"2023","journal-title":"Nat Med"},{"key":"2026100821100629000_5.1.e002780.49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/ds21-0108","article-title":"Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes","volume":"36","author":"Wettergreen","year":"2023","journal-title":"Diabetes Spectr"},{"key":"2026100821100629000_5.1.e002780.50","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-010942","article-title":"Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey","volume":"8","author":"Liu","year":"2023","journal-title":"BMJ Glob Health"},{"key":"2026100821100629000_5.1.e002780.51","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.4103\/jfmpc.jfmpc_605_24","article-title":"Which antidiabetic drugs do patients of T2DM prefer in India and why? A discrete choice experiment","volume":"13","author":"Vaidya","year":"2024","journal-title":"J Family Med Prim Care"},{"key":"2026100821100629000_5.1.e002780.52","article-title":"Willingness to Pay (WTP) for Newer Treatment Options for Diabetes: A Study Among Patients at a Tertiary Care Centre","volume":"16","author":"Vaidya","year":"2024","journal-title":"Cureus"},{"key":"2026100821100629000_5.1.e002780.53","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1080\/03007995.2024.2407960","article-title":"A discrete choice experiment to understand preferences of patients with type 2 diabetes about the attributes of GLP1 receptor agonists in Spain","volume":"40","author":"San Jos\u00e9","year":"2024","journal-title":"Curr Med Res Opin"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2026-002780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:10:20Z","timestamp":1791519020000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2026-002780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjmed-2026-002780"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2026-002780","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}